Roxadustat

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Normal Renal Function

Conditions

Normal Renal Function, Impaired Renal Function

Trial Timeline

Dec 12, 2016 → Dec 11, 2017

NCT ID

NCT02965040

About Roxadustat

Roxadustat is a phase 1 stage product being developed by Astellas Pharma for Normal Renal Function. The current trial status is completed. This product is registered under clinical trial identifier NCT02965040. Target conditions include Normal Renal Function, Impaired Renal Function.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05970172	Phase 3	Recruiting	Jan 16, 2024	Oct 30, 2027	Chronic Kidney Disease
NCT04408820	Pre-clinical	Completed	Jun 1, 2020	Jun 23, 2025	Renal Anemia
NCT04076943	Phase 2	Completed	Aug 20, 2019	Apr 23, 2021	Chemotherapy Induced Anemia
NCT03960489	Phase 1	Completed	Jul 31, 2019	Oct 14, 2019	Healthy Adult Subjects
NCT02964936	Phase 3	Completed	Jan 11, 2017	Aug 15, 2018	Chronic Kidney Disease
NCT02965040	Phase 1	Completed	Dec 12, 2016	Dec 11, 2017	Normal Renal Function
NCT02780726	Phase 3	Completed	Jun 22, 2016	Aug 2, 2017	Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
NCT02780141	Phase 3	Completed	Jun 2, 2016	Dec 12, 2017	ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
NCT02779764	Phase 3	Completed	May 16, 2016	Nov 28, 2017	Hemodialysis Patients With Renal Anemia
NCT01630889	Phase 2	Completed	May 18, 2012	Dec 12, 2019	Chronic Kidney Disease
NCT01244763	Phase 2	Completed	Oct 29, 2010	Jun 13, 2012	Chronic Kidney Disease
NCT01083888	Phase 1	Completed	Feb 15, 2010	Jun 7, 2010	Anemia

Competing Products

20 competing products in Normal Renal Function

See all competitors

Product	Company	Stage	Hype Score
Donepezil	Eisai	Approved	85
eribulin mesylate	Eisai	Phase 2	52
Lurasidone HCl	Sumitomo Pharma	Phase 1	33
Eybelis ophthalmic solution 0.002%	Santen Pharmaceutical	Approved	85
Triptorelin	Merck	Pre-clinical	23
Temozolomide + Vorinostat	Merck	Phase 2	52
LDE225	Novartis	Phase 1	33
LDK378	Novartis	Phase 1	33
cyclosporine micro-emulsion	Novartis	Approved	85
LDK378	Novartis	Phase 1	33
LEE011	Novartis	Phase 1	33
LEE011	Novartis	Phase 1	33
mycophenolate mofetil	Roche	Phase 1	33
filgrastim	Amgen	Pre-clinical	22
PF-06423264	Pfizer	Phase 1	32
PF-05221304	Pfizer	Phase 1	32
BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose Solution	Bristol Myers Squibb	Phase 1	32
tolebrutinib	Sanofi	Phase 1	32
Venglustat (GZ402671)	Sanofi	Phase 1	32
Rilzabrutinib	Sanofi	Phase 1	32

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved